[Drug lowering of the HDL concentration in the serum of cardiologically treated patients].
The connection between decreased concentration of HDL-cholesterol in the serum and increased risk of arteriosclerosis has attracted the attention to such sizes of influence which are able to decrease the HDL-cholesterol-concentration. In these cases the question is asked, whether the analytic reliability of the techniques which are at the disposal for the estimation of HDL-cholesterol is sufficient for the recognition of the changes of the concentration to be expected. To the sizes of influence belong medicaments which cannot be fancied away in the therapy of cardiovascular diseases; thus the beta-receptor blockers talinolol and propranolol. The examination of 118 cardiologically treated patients yields the result that there is no particular risk of the patients treated by means of these medicaments, since an essential decrease of the HDL-cholesterol-concentration could not be proved.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D002648:Child; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010417:Pentaerythritol Tetranitrate / Q000627:therapeutic use; D011412:Propanolamines / Q000009:adverse effects* / Q000627:therapeutic use; D011433:Propranolol / Q000009:adverse effects* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D008075:Lipoproteins, HDL; D011412:Propanolamines; D010417:Pentaerythritol Tetranitrate; C011550:talinolol; D011433:Propranolol
Untersuchungen zur medikamentösen Senkung der HDL-Konzentration im Serum bei kardiologisch betreuten Patienten.